TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07221357: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Sponsor: Bristol-Myers Squibb · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 990 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$676,368

Rescue Site Savings

+$450,912

Unlock Full NCT07221357 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07221357 Rescue Dossier →